Skip to main content

Advertisement

Log in

Pulmonary mucormycosis: clinical features and outcomes

  • Original Paper
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Purpose

Mucormycosis encompasses a group of opportunistic fungal infections caused by Zygomycetes, order Mucorales. Mucormycosis can manifest as rhino-orbito-cerebral, pulmonary, gastrointestinal, cutaneous, and disseminated infections. Pulmonary mucormycosis is the second most common presentation. This manuscript characterizes the demographics, clinical presentation, diagnostic procedures, radiologic findings, therapeutic interventions, and outcome in pulmonary mucormycosis.

Methods

We retrospectively reviewed clinical data of 35 patients with pulmonary mucormycosis from 2000 to 2015. Microbiologic diagnosis was based on positive culture from a sterile site or findings on histopathology consistent with mucormycosis. Independent predictors of 28-day mortality were assessed using logistic regression. Survival curves were estimated using Kaplan–Meier method.

Results

There was male predominance with a mean age of 55 ± 15 years. Analysis of predisposing conditions revealed the prevailing presence of malignancy. Sixty-six percent of patients were receiving immunosuppressive agents. Common presenting clinical findings were fever, neutropenia, dyspnea, and cough. Radiologic findings included pleural effusion and nodules. All patients received medical therapy and 43% underwent additional surgical intervention. Twenty eight day mortality was 29% with concurrent bacteremia found as the sole independent predictor. Similar survival from pulmonary mucormycosis was noted over time.

Conclusions

Pulmonary mucormycosis is an opportunistic angioinvasive fungal infection. Physicians must have a high level of suspicion in immunocompromised patients with fever and respiratory symptoms refractory to antibiotics. A low threshold should be had for performing an invasive procedure to gain reliable diagnosis, as early, aggressive medical and surgical interventions are needed for successful treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S, Lortholary O, et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med. 2015;36:692–705. doi:10.1055/s-0035-1562896.

    Article  PubMed  Google Scholar 

  2. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57:1044–50.

    Article  CAS  PubMed  Google Scholar 

  3. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15:1395–401. doi:10.3201/eid1509.090334.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital Belgium. Emerg Infect Dis. 2010;16:1456–8. doi:10.3201/eid1609.100276.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20:5–26. doi:10.1111/1469-0691.12371.

    Article  CAS  PubMed  Google Scholar 

  6. Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44:335–42. doi:10.1080/13693780500464930.

    Article  PubMed  Google Scholar 

  7. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60–6. doi:10.1086/430710.

    Article  PubMed  Google Scholar 

  8. Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta KL, et al. Ten yearsʼ experience in zygomycosis at a tertiary care centre in India. J Infect. 2001;42:261–6. doi:10.1053/jinf.2001.0831.

    Article  CAS  PubMed  Google Scholar 

  9. Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dellʼAdulto). Br J Haematol. 1997;99:331–6.

    Article  CAS  PubMed  Google Scholar 

  10. McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF Jr. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol. 1997;168:1541–8. doi:10.2214/ajr.168.6.9168721.

    Article  CAS  PubMed  Google Scholar 

  11. Saegeman V, Maertens J, Ectors N, Meersseman W, Lagrou K. Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. Med Mycol. 2010;48:245–54. doi:10.1080/13693780903059477.

    Article  CAS  PubMed  Google Scholar 

  12. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011;49:2151–3. doi:10.1128/jcm.00256-11.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Alvarez E, Sutton DA, Cano J, Fothergill AW, Stchigel A, Rinaldi MG, et al. Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol. 2009;47:1650–6. doi:10.1128/jcm.00036-09.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Marchiori E, Zanetti G, Escuissato DL, Souza AS Jr, Meirelles GS, Fagundes J, et al. Reversed halo sign: high-resolution CT scan findings in 79 patients. Chest. 2012;141:1260–6. doi:10.1378/chest.11-1050.

    Article  PubMed  Google Scholar 

  15. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126–33. doi:10.1128/aac.50.1.126-133.2006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–37. doi:10.1016/s1473-3099(16)00071-2.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Teng Moua.

Ethics declarations

Conflict of interest

The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. This research received no grant from any funding agency in the public, commercial or non-profit sectors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, E., Moua, T. & Limper, A.H. Pulmonary mucormycosis: clinical features and outcomes. Infection 45, 443–448 (2017). https://doi.org/10.1007/s15010-017-0991-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-017-0991-6

Keywords

Navigation